In many centres, brachytherapy is the first choice of treatment for uveal melanomas. This modality is also useful for some retinoblastomas and conjunctival melanomas. With this form of radiotherapy, a radioactive plaque containing ruthenium-106 or iodine-125 is sutured to the wall of the eye, adjacent to the tumor, and left in place for several days until the required dose of radiation has been delivered.

Eckert & Ziegler BEBIG offers a series of reliable products for temporary brachytherapy of eye cancers. The company is the only global provider of Ru-106 (Ruthenium-106) Eye Applicators used to treat ocular melanoma and retinoblastoma. The  product portfolio  also includes  the  COMS Eye  Applicators used  together with the IsoSeed® I-125.